Nilsine Partners LLC Sells 38,901 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nilsine Partners LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 90.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,975 shares of the medical equipment provider's stock after selling 38,901 shares during the period. Nilsine Partners LLC's holdings in Hologic were worth $246,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Smithfield Trust Co lifted its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares in the last quarter. Finally, Raiffeisen Bank International AG acquired a new position in shares of Hologic during the fourth quarter valued at about $49,000. 94.73% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Stock Performance

HOLX traded up $0.40 during midday trading on Tuesday, reaching $64.83. The company had a trading volume of 2,236,845 shares, compared to its average volume of 2,357,866. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The business has a 50-day moving average price of $59.55 and a two-hundred day moving average price of $64.21. The stock has a market cap of $14.45 billion, a PE ratio of 27.35, a P/E/G ratio of 2.36 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the business earned $1.03 earnings per share. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on HOLX shares. Evercore ISI lowered their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada lowered their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Stephens dropped their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.